Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1381 participants.
Also called NCT01303783
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 1,381 participants
- Sponsor
- Registry
-
NCT01303783 -
2009-017077-37
-
- Other papers using this trial's data
- Nifedipine GITS/Candesartan Combination Therapy Lowers Blood Pressure Across Different Baseline Systolic and Diastolic Blood Pressure Categories: DISTINCT Study Subanalyses
- Nifedipine plus candesartan combination increases blood pressure control regardless of race and improves the side effect profile: DISTINCT randomized trial results
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Argentina, Belgium, Brazil, Canada, Italy, Lithuania, Russia, South Africa, South Korea, Spain, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01303783. Randomized; quadruple masking; primary purpose treatment. Start 2011-04 (registry gives no type); primary completion 2012-05 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension
- Acronym
- DISTINCT
- Condition
- Hypertension, Essential
- Intervention (Drug)
- Candesartan cilexetil (Atacand), 4 mg
- Intervention (Drug)
- Candesartan cilexetil (Atacand), 8 mg
- Intervention (Drug)
- Nifedipine GITS (Adalat, BAYA1040), 20 mg
- Intervention (Drug)
- Nifedipine GITS (Adalat, BAYA1040), 30 mg
- Intervention (Drug)
- Nifedipine GITS (Adalat, BAYA1040), 60 mg
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Candesartan cilexetil (Atacand), 16 mg
- Intervention (Drug)
- Candesartan cilexetil (Atacand), 32 mg
- Lead sponsor
- Bayer
Record details
- Record id
cardio:ct-nct01303783- Content hash
35c85d0502183ff0c043d80364b3f910b992b5ed72912e9df5d4696b1f73fdf0